Back

Targeting CPSF73, the mRNA 3' End Processing Endonuclease, Moves Cancer Cells Away from the Mesenchymal State

Naseri, M.; Liu, H.; Wang, L.; Mohd Mostafa, S.; Ranaei Pirmardan, E.; Tian, B.; Moore, C.

2026-03-03 cancer biology
10.64898/2026.03.01.708894 bioRxiv
Show abstract

BackgroundMetastasis significantly contributes to cancer-related mortality and therapeutic failure. Cancer cells acquire metastatic potential by losing epithelial characteristics and gaining mesenchymal properties through the epithelial-mesenchymal transition (EMT). Differential poly(A) site (PAS) usage, known as alternative polyadenylation (APA), generates mRNA isoforms differing in coding sequence, subcellular localization, stability, or translation efficiency. In cancer, 3'UTR shortening increases expression of proto-oncogenes by escaping miRNA-mediated repression. High expression of CPSF73, which cleaves mRNA precursors at PASs, is associated with unfavorable prognoses in cancer patients. However, the role of APA in regulating EMT remains poorly understood. MethodsIn this study, to investigate the role of APA in EMT, we employed JTE-607, a small-molecule inhibitor of CPSF73 activity, to examine the impact of catalytic inhibition of CPSF73 on proliferation and EMT in MDA-MB-231, MCF7, A549, and HepG2 cancer cells. To identify differential usage of PASs, global profiling of APA changes, and differential gene expression analysis were performed in MDA-MB-231 cells. Additionally, antisense oligonucleotides were used to block the use of a specific PAS whose APA change may be a driver of EMT reversal. ResultsOur findings showed that catalytic inhibition of CPSF73 not only attenuates cancer cell proliferation but also moves the cells away from the mesenchymal state across all four cell lines tested. Global profiling of APA changes following CPSF73 inhibition revealed widespread 3'UTR lengthening and suppression of intronic PASs in MDA-MB-231 cells. APA shifts were observed in key EMT-related genes, accompanied by decreased expression of corresponding proteins across all four cell lines. We used antisense morpholino oligonucleotides to block the proximal PAS of AKT2, shifting the balance of AKT2 mRNA isoforms toward the long isoform. This shift caused EMT reversal, marked by reduced AKT2 protein expression, changes in EMT-related markers, and impaired invasion by MDA-MB-231 cells. ConclusionTogether, these findings identify APA-mediated 3UTR lengthening, with functional consequences in EMT-related genes, as a coordinated mechanism leading to an attenuated EMT phenotype, highlighting a significant connection between APA and the EMT process. Interfering with these APA changes may offer a promising therapeutic strategy to suppress metastasis, with potential efficacy across multiple pathways. Statement of SignificanceOur findings highlight APA-mediated 3 UTR lengthening as a coordinated mechanism that promotes EMT reversal and support CPSF73 inhibition or APA-targeting strategies as potential therapeutic approaches to suppress metastasis across multiple pathways.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
International Journal of Cancer
42 papers in training set
Top 0.1%
19.6%
2
BMC Cancer
52 papers in training set
Top 0.2%
8.3%
3
Frontiers in Oncology
95 papers in training set
Top 0.4%
6.9%
4
Cancers
200 papers in training set
Top 0.8%
6.4%
5
PLOS ONE
4510 papers in training set
Top 31%
4.9%
6
PeerJ
261 papers in training set
Top 1%
4.3%
50% of probability mass above
7
Cancer Letters
32 papers in training set
Top 0.1%
4.0%
8
Scientific Reports
3102 papers in training set
Top 36%
3.6%
9
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.3%
2.1%
10
Molecular Cancer Therapeutics
33 papers in training set
Top 0.3%
2.1%
11
British Journal of Cancer
42 papers in training set
Top 0.6%
2.1%
12
eLife
5422 papers in training set
Top 41%
1.7%
13
Cancer Medicine
24 papers in training set
Top 0.7%
1.7%
14
Oncogene
76 papers in training set
Top 1%
1.3%
15
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
16
Journal of Translational Medicine
46 papers in training set
Top 1%
1.2%
17
Translational Oncology
18 papers in training set
Top 0.3%
1.0%
18
Biochemistry and Biophysics Reports
28 papers in training set
Top 1%
1.0%
19
Oncotarget
15 papers in training set
Top 0.3%
0.9%
20
Neoplasia
22 papers in training set
Top 0.6%
0.8%
21
Cells
232 papers in training set
Top 6%
0.8%
22
International Journal of Molecular Sciences
453 papers in training set
Top 15%
0.8%
23
BMC Biology
248 papers in training set
Top 4%
0.8%
24
NAR Cancer
36 papers in training set
Top 0.1%
0.8%
25
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%
26
The FASEB Journal
175 papers in training set
Top 4%
0.7%
27
Journal of Medical Genetics
28 papers in training set
Top 0.6%
0.7%
28
Human Molecular Genetics
130 papers in training set
Top 4%
0.7%
29
Biochemical Pharmacology
18 papers in training set
Top 0.2%
0.7%
30
Frontiers in Endocrinology
53 papers in training set
Top 2%
0.7%